Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Carla, Abdelnour Ruiz"'
Autor:
Federico Rodriguez-Porcel, Kathryn A. Wyman-Chick, Carla Abdelnour Ruiz, Jon B. Toledo, Daniel Ferreira, Prabitha Urwyler, Rimona S. Weil, Joseph Kane, Andrea Pilotto, Arvid Rongve, Bradley Boeve, John-Paul Taylor, Ian McKeith, Dag Aarsland, Simon J. G. Lewis, the Lewy Body Dementias Clinical Trials Workgroup from the Lewy Body Dementias Professional Interest Area - Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART)
Publikováno v:
Translational Neurodegeneration, Vol 11, Iss 1, Pp 1-18 (2022)
Abstract The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit i
Externí odkaz:
https://doaj.org/article/6058a154f53c4fd0b938c4c0b34ec507
Autor:
Federico Rodriguez-Porcel, Kathryn A. Wyman-Chick, Carla Abdelnour Ruiz, Jon B. Toledo, Daniel Ferreira, Prabitha Urwyler, Rimona S. Weil, Joseph Kane, Andrea Pilotto, Arvid Rongve, Bradley Boeve, John-Paul Taylor, Ian McKeith, Dag Aarsland, Simon J. G. Lewis, the Lewy Body Dementias Clinical Trials Workgroup from the Lewy Body Dementias Professional Interest Area - Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART)
Publikováno v:
Translational Neurodegeneration, Vol 11, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/35c0f8e869484f1cb49f4fb1335b03d4
Autor:
Carla Abdelnour Ruiz
Publikováno v:
Revista Kranion. 16
Autor:
Federico, Rodriguez-Porcel, Kathryn A, Wyman-Chick, Carla, Abdelnour Ruiz, Jon B, Toledo, Daniel, Ferreira, Prabitha, Urwyler, Rimona S, Weil, Joseph, Kane, Andrea, Pilotto, Arvid, Rongve, Bradley, Boeve, John-Paul, Taylor, Ian, McKeith, Dag, Aarsland, Simon J G, Lewis
Publikováno v:
Translational neurodegeneration. 11(1)
The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinica